B cells in autoimmune hepatitis: bystanders or central players?

1.

Mieli-Vergani G, Vergani D, Czaja AJ, Manns MP, Krawitt EL, Vierling JM et al (2018) Autoimmune hepatitis Nat Rev Dis Primers 4:18017. https://doi.org/10.1038/nrdp.2018.17CrossRefPubMed

2.

Krawitt EL (2006) Autoimmune hepatitis. N Engl J Med 354(1):54–66. https://doi.org/10.1056/NEJMra050408CrossRefPubMed

3.

Terziroli Beretta-Piccoli B, Mieli-Vergani G, Vergani D (2021) Autoimmmune hepatitis. Cell Mol Immunol. https://doi.org/10.1038/s41423-021-00768-8CrossRefPubMedPubMedCentral

4.

Lohse AW, Mieli-Vergani G (2011) Autoimmune hepatitis. J Hepatol 55(1):171–182. https://doi.org/10.1016/j.jhep.2010.12.012CrossRefPubMed

5.

Lohse AW, Weiler-Normann C, Tiegs G (2010) Immune-mediated liver injury. J Hepatol 52(1):136–144. https://doi.org/10.1016/j.jhep.2009.10.016CrossRefPubMed

6.

Cooper MD (2015) The early history of B cells. Nat Rev Immunol 15(3):191–197. https://doi.org/10.1038/nri3801CrossRefPubMed

7.

Hardy RR, Hayakawa K (2001) B cell development pathways. Annu Rev Immunol 19:595–621. https://doi.org/10.1146/annurev.immunol.19.1.595CrossRefPubMed

8.

Herzog S, Reth M, Jumaa H (2009) Regulation of B-cell proliferation and differentiation by pre-B-cell receptor signalling. Nat Rev Immunol 9(3):195–205. https://doi.org/10.1038/nri2491CrossRefPubMed

9.

Melchers F (2015) Checkpoints that control B cell development. J Clin Invest 125(6):2203–2210. https://doi.org/10.1172/JCI78083CrossRefPubMedPubMedCentral

10.

Pieper K, Grimbacher B, Eibel H (2013) B-cell biology and development. J Allergy Clin Immunol 131(4):959–971. https://doi.org/10.1016/j.jaci.2013.01.046CrossRefPubMed

11.

Cyster JG, Allen CDC (2019) B Cell responses: cell interaction dynamics and decisions. Cell 177(3):524–540. https://doi.org/10.1016/j.cell.2019.03.016CrossRefPubMedPubMedCentral

12.

De Silva NS, Klein U (2015) Dynamics of B cells in germinal centres. Nat Rev Immunol 15(3):137–148. https://doi.org/10.1038/nri3804CrossRefPubMedPubMedCentral

13.

Stebegg M, Kumar SD, Silva-Cayetano A, Fonseca VR, Linterman MA, Graca L (2018) Regulation of the germinal center response. Front Immunol 9:2469. https://doi.org/10.3389/fimmu.2018.02469CrossRefPubMedPubMedCentral

14.

Ludwig RJ, Vanhoorelbeke K, Leypoldt F, Kaya Z, Bieber K, McLachlan SM et al (2017) Mechanisms of autoantibody-induced pathology. Front Immunol 8:603. https://doi.org/10.3389/fimmu.2017.00603CrossRefPubMedPubMedCentral

15.

Robles DT, Eisenbarth GS, Dailey NJ, Peterson LB, Wicker LS (2003) Insulin autoantibodies are associated with islet inflammation but not always related to diabetes progression in NOD congenic mice. Diabetes 52(3):882–886. https://doi.org/10.2337/diabetes.52.3.882CrossRefPubMed

16.

Taplin CE, Barker JM (2008) Autoantibodies in type 1 diabetes. Autoimmunity 41(1):11–18. https://doi.org/10.1080/08916930701619169CrossRefPubMed

17.

Jahns R, Boivin V, Schwarzbach V, Ertl G, Lohse MJ (2008) Pathological autoantibodies in cardiomyopathy. Autoimmunity 41(6):454–461. https://doi.org/10.1080/08916930802031603CrossRefPubMed

18.

Caforio AL, Tona F, Bottaro S, Vinci A, Dequal G, Daliento L et al (2008) Clinical implications of anti-heart autoantibodies in myocarditis and dilated cardiomyopathy. Autoimmunity 41(1):35–45. https://doi.org/10.1080/08916930701619235CrossRefPubMed

19.

Didona D, Maglie R, Eming R, Hertl M (2019) Pemphigus: current and future therapeutic strategies. Front Immunol 10:1418. https://doi.org/10.3389/fimmu.2019.01418CrossRefPubMedPubMedCentral

20.

Bax M, Huizinga TW, Toes RE (2014) The pathogenic potential of autoreactive antibodies in rheumatoid arthritis. Semin Immunopathol 36(3):313–325. https://doi.org/10.1007/s00281-014-0429-5CrossRefPubMed

21.

van Delft MAM, Huizinga TWJ (2020) An overview of autoantibodies in rheumatoid arthritis. J Autoimmun 110:102392. https://doi.org/10.1016/j.jaut.2019.102392CrossRefPubMed

22.

Care MA, Stephenson SJ, Barnes NA, Fan I, Zougman A, El-Sherbiny YM et al (2016) Network analysis identifies proinflammatory plasma cell polarization for secretion of ISG15 in human autoimmunity. J Immunol 197(4):1447–1459. https://doi.org/10.4049/jimmunol.1600624CrossRefPubMedPubMedCentral

23.

Linterman MA, Rigby RJ, Wong RK, Yu D, Brink R, Cannons JL et al (2009) Follicular helper T cells are required for systemic autoimmunity. J Exp Med 206(3):561–576. https://doi.org/10.1084/jem.20081886CrossRefPubMedPubMedCentral

24.

Elsner RA, Shlomchik MJ (2020) Germinal center and extrafollicular B cell responses in vaccination, immunity, and autoimmunity. Immunity 53(6):1136–1150. https://doi.org/10.1016/j.immuni.2020.11.006CrossRefPubMedPubMedCentral

25.

Rahim MN, Miquel R, Heneghan MA (2020) Approach to the patient with acute severe autoimmune hepatitis. JHEP Rep 2(6):100149. https://doi.org/10.1016/j.jhepr.2020.100149CrossRefPubMedPubMedCentral

26.

Weiler-Normann C, Lohse AW (2021) Autoimmune hepatitis: from immunopathogenesis to diagnostic and therapeutic innovation. Curr Opin Gastroenterol 37(2):86–90. https://doi.org/10.1097/MOG.0000000000000701CrossRefPubMed

27.

Herkel J, Carambia A, Lohse AW (2020) Autoimmune hepatitis: possible triggers, potential treatments. J Hepatol 73(2):446–448. https://doi.org/10.1016/j.jhep.2020.03.015CrossRefPubMed

28.

Hennes EM, Zeniya M, Czaja AJ, Pares A, Dalekos GN, Krawitt EL et al (2008) Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 48(1):169–176. https://doi.org/10.1002/hep.22322CrossRefPubMed

29.

Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL et al (1999) International autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 31(5):929–938. https://doi.org/10.1016/s0168-8278(99)80297-9CrossRefPubMed

30.

de Boer YS, van Nieuwkerk CM, Witte BI, Mulder CJ, Bouma G, Bloemena E (2015) Assessment of the histopathological key features in autoimmune hepatitis. Histopathology 66(3):351–362. https://doi.org/10.1111/his.12558CrossRefPubMed

31.

Balitzer D, Shafizadeh N, Peters MG, Ferrell LD, Alshak N, Kakar S (2017) Autoimmune hepatitis: review of histologic features included in the simplified criteria proposed by the international autoimmune hepatitis group and proposal for new histologic criteria. Mod Pathol 30(5):773–783. https://doi.org/10.1038/modpathol.2016.267CrossRefPubMed

32.

Gurung A, Assis DN, McCarty TR, Mitchell KA, Boyer JL, Jain D (2018) Histologic features of autoimmune hepatitis: a critical appraisal. Hum Pathol 82:51–60. https://doi.org/10.1016/j.humpath.2018.07.014CrossRefPubMed

33.

Bach N, Thung SN, Schaffner F (1992) The histological features of chronic hepatitis C and autoimmune chronic hepatitis: a comparative analysis. Hepatology 15(4):572–577. https://doi.org/10.1002/hep.1840150403CrossRefPubMed

34.

Czaja AJ, Carpenter HA (1993) Sensitivity, specificity, and predictability of biopsy interpretations in chronic hepatitis. Gastroenterology 105(6):1824–1832. https://doi.org/10.1016/0016-5085(93)91081-rCrossRefPubMed

35.

Crawford AR, Lin XZ, Crawford JM (1998) The normal adult human liver biopsy: a quantitative reference standard. Hepatology 28(2):323–331. https://doi.org/10.1002/hep.510280206CrossRefPubMed

36.

Covelli C, Sacchi D, Sarcognato S, Cazzagon N, Grillo F, Baciorri F et al (2021) Pathology of autoimmune hepatitis. Pathologica 113(3):185–93. https://doi.org/10.32074/1591-951X-241CrossRefPubMedPubMedCentral

37.

European Association for the Study of the Liver (2015) EASL clinical practice guidelines: autoimmune hepatitis. J Hepatol 63(4):971–1004. https://doi.org/10.1016/j.jhep.2015.06.030

38.

Schultheiss C, Paschold L, Willscher E, Simnica D, Wostemeier A, Muscate F et al (2021) Maturation trajectories and transcriptional landscape of plasmablasts and autoreactive B cells in COVID-19. IScience 24(11):103325. https://doi.org/10.1016/j.isci.2021.103325CrossRefPubMedPubMedCentral

39.

Wucherpfennig KW (2001) Mechanisms for the induction of autoimmunity by infectious agents. J Clin Invest 108(8):1097–1104. https://doi.org/10.1172/JCI14235CrossRefPubMedPubMedCentral

40.

Chakravarty EF (2008) Viral infection and reactivation in autoimmune disease. Arthritis Rheum 58(10):2949–2957. https://doi.org/10.1002/art.23883CrossRefPubMed

41.

Gilman AJ, Le AK, Zhao C, Hoang J, Yasukawa LA, Weber SC et al (2018) Autoantibodies in chronic hepatitis C virus infection: impact on clinical outcomes and extrahepatic manifestations. BMJ Open Gastroenterol 5(1):e000203. https://doi.org/10.1136/bmjgast-2018-000203CrossRefPubMedPubMedCentral

42.

Baeres M, Herkel J, Czaja AJ, Wies I, Kanzler S, Cancado EL et al (2002) Establishment of standardised SLA/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics. Gut 51(2):259–264. https://doi.org/10.1136/gut.51.2.259CrossRefPubMedPubMedCentral

43.

Herkel J, Heidrich B, Nieraad N, Wies I, Rother M, Lohse AW (2002) Fine specificity of autoantibodies to soluble liver antigen and liver/pancreas. Hepatology 35(2):403–408. https://doi.org/10.1053/jhep.2002.30699CrossRefPubMed

44.

Lohse AW, Gerken G, Altes U, Mayet WJ, Meyer zumBuschenfelde KH (1993) Transmission of maternal IgG autoantibodies via cord blood and breastmilk without transmission of hepatitis. Lancet 341(8854):1216–7. https://doi.org/10.1016/0140-6736(93)91046-oCrossRefPubMed

45.

Zhang WC, Zhao FR, Chen J, Chen WX (2014) Meta-analysis: diagnostic accuracy of antinuclear antibodies, smooth muscle antibodies and antibodies to a soluble liver antigen/liver pancreas in autoimmune hepatitis. PLoS ONE 9(3):e92267. https://doi.org/10.1371/journal.pone.0092267CrossRefPubMedPubMedCentral

46.

Zingaretti C, Arigo M, Cardaci A, Moro M, Crosti M, Sinisi A et al (2012) Identification of new autoantigens by protein array indicates a role for IL4 neutralization in autoimmune hepatitis. Mol Cell Proteomics 11(12):1885–1897. https://doi.org/10.1074/mcp.M112.018713CrossRefPubMedPubMedCentral

47.

Song Q, Liu G, Hu S, Zhang Y, Tao Y, Han Y et al (2010) Novel autoimmune hepatitis-specific autoantigens identified using protein microarray technology. J Proteome Res 9(1):30–39. https://doi.org/10.1021/pr900131eCrossRefPubMedPubMedCentral

48.

Lammert C, Zhu C, Lian Y, Raman I, Eckert G, Li QZ et al (2020) Exploratory study of autoantibody profiling in drug-induced liver injury with an autoimmune phenotype. Hepatol Commun 4(11):1651–1663. https://doi.org/10.1002/hep4.1582CrossRefPubMedPubMedCentral

49.

Zhang W, Rho JH, Roehrl MH, Wang JY (2019) A comprehensive autoantigen-ome of autoimmune liver diseases identified from dermatan sulfate affinity enrichment of liver tissue proteins. BMC Immunol 20(1):21. https://doi.org/10.1186/s12865-019-0304-1CrossRefPubMedPubMedCentral

50.

Taubert R, Engel B, Diestelhorst J, Hupa-Breier KL, Behrendt P, Baerleckeen NT et al (2021) Quantification of polyreactive immunoglobulin G facilitates the diagnosis of autoimmune hepatitis. Hepatology 75(1):13–27. https://doi.org/10.1002/hep.32134

51.

Matsumoto K, Miyake Y, Matsushita H, Ohnishi A, Ikeda F, Shiraha H et al (2014) Anti-programmed cell death-1 antibody as a new serological marker for type 1 autoimmune hepatitis. J Gastroenterol Hepatol 29(1):110–115. https://doi.org/10.1111/jgh.12340CrossRefPubMed

52.

Francisco LM, Sage PT, Sharpe AH (2010) The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 236:219–242. https://doi.org/10.1111/j.1600-065X.2010.00923.xCrossRefPubMedPubMedCentral

53.

Qin W, Hu L, Zhang X, Jiang S, Li J, Zhang Z et al (2019) The diverse function of PD-1/PD-L pathway beyond cancer. Front Immunol 10:2298. https://doi.org/10.3389/fimmu.2019.02298CrossRefPubMedPubMedCentral

54.

Okazaki T, Honjo T (2006) The PD-1-PD-L pathway in immunological tolerance. Trends Immunol 27(4):195–201. https://doi.org/10.1016/j.it.2006.02.001CrossRefPubMed

55.

Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M et al (2019) Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol 16(9):563–580. https://doi.org/10.1038/s41571-019-0218-0CrossRefPubMed

56.

Aarslev K, Dige A, Greisen SR, Kreutzfeldt M, Jessen N, Vilstrup H et al (2017) Soluble programmed death-1 levels are associated with disease activity and treatment response in patients with autoimmune hepatitis. Scand J Gastroenterol 52(1):93–99. https://doi.org/10.1080/00365521.2016.1233576CrossRefPubMed

57.

Hadley T, Gillespie S, Espinoza H, Prince J, Gronbaek H, Chandrakasan S et al (2020) Soluble PD1 levels are increased with disease activity in paediatric onset autoimmune hepatitis and inflammatory bowel disease. Autoimmunity 53(5):253–260. https://doi.org/10.1080/08916934.2020.1755964CrossRefPubMed

58.

Gu D, Ao X, Yang Y, Chen Z, Xu X (2018) Soluble immune checkpoints in cancer: production, function and biological significance. J Immunother Cancer 6(1):132. https://doi.org/10.1186/s40425-018-0449-0CrossRefPubMedPubMedCentral

59.

Curran CS, Sharon E (2017) PD-1 immunobiology in autoimmune hepatitis and hepatocellular carcinoma. Semin Oncol 44(6):428–432. https://doi.org/10.1053/j.seminoncol.2017.12.001CrossRefPubMed

60.

Thomson AW, Knolle PA (2010) Antigen-presenting cell function in the tolerogenic liver environment. Nat Rev Immunol 10(11):753–766. https://doi.org/10.1038/nri2858CrossRefPubMed

61.

Luth S, Herkel J, Kanzler S, Frenzel C, Galle PR, Dienes HP et al (2008) Serologic markers compared with liver biopsy for monitoring disease activity in autoimmune hepatitis. J Clin Gastroenterol 42(8):926–930. https://doi.org/10.1097/MCG.0b013e318154af74CrossRefPubMed

62.

Hartl J, Ehlken H, Sebode M, Peiseler M, Krech T, Zenouzi R et al (2018) Usefulness of biochemical remission and transient elastography in monitoring disease course in autoimmune hepatitis. J Hepatol 68(4):754–763. https://doi.org/10.1016/j.jhep.2017.11.020CrossRefPubMed

63.

Hartl J, Miquel R, Zachou K, Wong GW, Asghar A, Pape S et al (2020) Features and outcome of AIH patients without elevation of IgG. JHEP Rep 2(3):100094. https://doi.org/10.1016/j.jhepr.2020.100094CrossRefPubMedPubMedCentral

64.

Jonsson S, Sveinbjornsson G, de Lapuente Portilla AL, Swaminathan B, Plomp R, Dekkers G et al (2017) Identification of sequence variants influencing immunoglobulin levels. Nat Genet 49(8):1182–1191. https://doi.org/10.1038/ng.3897CrossRefPubMed

65.

Abokor AA, McDaniel GH, Golonka RM, Campbell C, Brahmandam S, Yeoh BS et al (2021) Immunoglobulin A, an active liaison for host-microbiota homeostasis. Microorganisms 9(10):2117. https://doi.org/10.3390/microorganisms9102117

66.

Yuksel M, Wang Y, Tai N, Peng J, Guo J, Beland K et al (2015) A novel “humanized mouse” model for autoimmune hepatitis and the association of gut microbiota with liver inflammation. Hepatology 62(5):1536–1550. https://doi.org/10.1002/hep.27998CrossRefPubMed

67.

Lin R, Zhou L, Zhang J, Wang B (2015) Abnormal intestinal permeability and microbiota in patients with autoimmune hepatitis. Int J Clin Exp Pathol 8(5):5153–5160PubMedPubMedCentral

68.

Manfredo Vieira S, Hiltensperger M, Kumar V, Zegarra-Ruiz D, Dehner C, Khan N et al (2018) Translocation of a gut pathobiont drives autoimmunity in mice and humans. Science 359(6380):1156–1161. https://doi.org/10.1126/science.aar7201CrossRefPubMed

69.

Vergani D, Mieli-Vergani G, Mondelli M, Portmann B, Eddleston AL (1987) Immunoglobulin on the surface of isolated hepatocytes is associated with antibody-dependent cell-mediated cytotoxicity and liver damage. Liver 7(6):307–315. https://doi.org/10.1111/j.1600-0676.1987.tb00361.xCrossRefPubMed

70.

Manns M, Zanger U, Gerken G, Sullivan KF, Meyer zumBuschenfelde KH, Meyer UA et al (1990) Patients with type II autoimmune hepatitis express functionally intact cytochrome P-450 db1 that is inhibited by LKM-1 autoantibodies in vitro but not in vivo. Hepatology 12(1):127–32. https://doi.org/10.1002/hep.1840120120CrossRefPubMed

71.

Muratori L, Parola M, Ripalti A, Robino G, Muratori P, Bellomo G et al (2000) Liver/kidney microsomal antibody type 1 targets CYP2D6 on hepatocyte plasma membrane. Gut 46(4):553–561. https://doi.org/10.1136/gut.46.4.553CrossRefPubMedPubMedCentral

72.

Hardtke-Wolenski M, Fischer K, Noyan F, Schlue J, Falk CS, Stahlhut M et al (2013) Genetic predisposition and environmental danger signals initiate chronic autoimmune hepatitis driven by CD4+ T cells. Hepatology 58(2):718–728. https://doi.org/10.1002/hep.26380CrossRefPubMed

73.

Schramm C, Herkel J, Beuers U, Kanzler S, Galle PR, Lohse AW (2006) Pregnancy in autoimmune hepatitis: outcome and risk factors. Am J Gastroenterol 101(3):556–560. https://doi.org/10.1111/j.1572-0241.2006.00479.xCrossRefPubMed

74.

Wang CW, Grab J, Tana MM, Irani RA, Sarkar M (2021) Outcomes of pregnancy in autoimmune hepatitis: a population-based study. Hepatology 75(1):5–12. https://doi.org/10.1002/hep.32132

75.

Abe K, Takahashi A, Imaizumi H, Hayashi M, Okai K, Kanno Y et al (2016) Interleukin-21 plays a critical role in the pathogenesis and severity of type I autoimmune hepatitis. Springerplus 5(1):777. https://doi.org/10.1186/s40064-016-2512-yCrossRefPubMedPubMedCentral

76.

Ma L, Qin J, Ji H, Zhao P, Jiang Y (2014) Tfh and plasma cells are correlated with hypergammaglobulinaemia in patients with autoimmune hepatitis. Liver Int 34(3):405–415. https://doi.org/10.1111/liv.12245CrossRefPubMed

77.

Ozaki K, Spolski R, Ettinger R, Kim HP, Wang G, Qi CF et al (2004) Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6. J Immunol 173(9):5361–5371. https://doi.org/10.4049/jimmunol.173.9.5361CrossRefPubMed

78.

Ozaki K, Spolski R, Feng CG, Qi CF, Cheng J, Sher A et al (2002) A critical role for IL-21 in regulating immunoglobulin production. Science 298(5598):1630–1634. https://doi.org/10.1126/science.1077002CrossRefPubMed

79.

Wang X, Wong K, Ouyang W, Rutz S (2019) Targeting IL-10 family cytokines for the treatment of human diseases. Cold Spring Harb Perspect Biol 11(2). https://doi.org/10.1101/cshperspect.a028548

80.

Chaudhry A, Samstein RM, Treuting P, Liang Y, Pils MC, Heinrich JM et al (2011) Interleukin-10 signaling in regulatory T cells is required for suppression of Th17 cell-mediated inflammation. Immunity 34(4):566–578. https://doi.org/10.1016/j.immuni.2011.03.018CrossRefPubMedPubMedCentral

81.

Abe M, Hiasa Y, Onji M (2013) T helper 17 cells in autoimmune liver diseases. Clin Dev Immunol 2013:607073. https://doi.org/10.1155/2013/607073CrossRefPubMedPubMedCentral

82.

Malisan F, Briere F, Bridon JM, Harindranath N, Mills FC, Max EE et al (1996) Interleukin-10 induces immunoglobulin G isotype switch recombination in human CD40-activated naive B lymphocytes. J Exp Med 183(3):937–947. https://doi.org/10.1084/jem.183.3.937CrossRefPubMed

83.

Llorente L, Zou W, Levy Y, Richaud-Patin Y, Wijdenes J, Alcocer-Varela J et al (1995) Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J Exp Med 181(3):839–844. https://doi.org/10.1084/jem.181.3.839CrossRefPubMed

84.

Geginat J, Larghi P, Paroni M, Nizzoli G, Penatti A, Pagani M et al (2016) The light and the dark sides of Interleukin-10 in immune-mediated diseases and cancer. Cytokine Growth Factor Rev 30:87–93. https://doi.org/10.1016/j.cytogfr.2016.02.003CrossRefPubMed

85.

Laman JD, Claassen E, Noelle RJ (1996) Functions of CD40 and its ligand, gp39 (CD40L). Crit Rev Immunol 16(1):59–108. https://doi.org/10.1615/critrevimmunol.v16.i1.40CrossRefPubMed

86.

Schultheiss C, Paschold L, Simnica D, Mohme M, Willscher E, von Wenserski L et al (2020) Next-generation sequencing of T and B cell receptor repertoires from COVID-19 patients showed signatures associated with severity of disease. Immunity 53(2):442–55 e4. https://doi.org/10.1016/j.immuni.2020.06.024CrossRefPubMedPubMedCentral

87.

Simnica D, Smits M, Willscher E, Fanchi LF, Kloots ISH, Iv Oort et al (2020) Responsiveness to immune checkpoint inhibitors is associated with a peripheral blood T-cell signature in metastatic castration-resistant prostate cancer. JCO Precision Oncology 4:1374–85. https://doi.org/10.1200/po.20.00209CrossRefPubMed

88.

Bashford-Rogers RJM, Bergamaschi L, McKinney EF, Pombal DC, Mescia F, Lee JC et al (2019) Analysis of the B cell receptor repertoire in six immune-mediated diseases. Nature 574(7776):122–126. https://doi.org/10.1038/s41586-019-1595-3CrossRefPubMedPubMedCentral

89.

Schultheiss C, Simnica D, Willscher E, Oberle A, Fanchi L, Bonzanni N et al (2021) Next-generation immunosequencing reveals pathological T-cell architecture in autoimmune hepatitis. Hepatology 73(4):1436–1448. https://doi.org/10.1002/hep.31473CrossRefPubMed

90.

Renand A, Habes S, Mosnier JF, Auble H, Judor JP, Vince N et al (2018) Immune alterations in patients with type 1 autoimmune hepatitis persist upon standard immunosuppressive treatment. Hepatol Commun 2(8):968–981. https://doi.org/10.1002/hep4.1202CrossRefPubMedPubMedCentral

91.

Taylor SA, Assis DN, Mack CL (2019) The contribution of B cells in autoimmune liver diseases. Semin Liver Dis 39(4):422–431. https://doi.org/10.1055/s-0039-1688751CrossRefPubMedPubMedCentral

92.

Czaja AJ (2021) Review article: targeting the B cell activation system in autoimmune hepatitis. Aliment Pharmacol Ther 54(7):902–922. https://doi.org/10.1111/apt.16574CrossRefPubMed

93.

Neefjes J, Jongsma ML, Paul P, Bakke O (2011) Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nat Rev Immunol 11(12):823–836. https://doi.org/10.1038/nri3084CrossRefPubMed

94.

Fasano R, Malerba E, Prete M, Solimando AG, Buonavoglia A, Silvestris N et al (2021) Impact of antigen presentation mechanisms on immune response in autoimmune hepatitis. Front Immunol 12:814155. https://doi.org/10.3389/fimmu.2021.814155CrossRefPubMed

95.

Shlomchik MJ (2008) Sites and stages of autoreactive B cell activation and regulation. Immunity 28(1):18–28. https://doi.org/10.1016/j.immuni.2007.12.004CrossRefPubMed

96.

Adler LN, Jiang W, Bhamidipati K, Millican M, Macaubas C, Hung SC et al (2017) The other function: class II-restricted antigen presentation by B cells. Front Immunol 8:319. https://doi.org/10.3389/fimmu.2017.00319CrossRefPubMedPubMedCentral

97.

Rodriguez-Pinto D, Moreno J (2005) B cells can prime naive CD4+ T cells in vivo in the absence of other professional antigen-presenting cells in a CD154-CD40-dependent manner. Eur J Immunol 35(4):1097–1105. https://doi.org/10.1002/eji.200425732CrossRefPubMed

98.

Crawford A, Macleod M, Schumacher T, Corlett L, Gray D (2006) Primary T cell expansion and differentiation in vivo requires antigen presentation by B cells. J Immunol 176(6):3498–3506. https://doi.org/10.4049/jimmunol.176.6.3498CrossRefPubMed

99.

Beland K, Marceau G, Labardy A, Bourbonnais S, Alvarez F (2015) Depletion of B cells induces remission of autoimmune hepatitis in mice through reduced antigen presentation and help to T cells. Hepatology 62(5):1511–1523. https://doi.org/10.1002/hep.27991CrossRefPubMed

100.

Barnett LG, Simkins HM, Barnett BE, Korn LL, Johnson AL, Wherry EJ et al (2014) B cell antigen presentation in the initiation of follicular helper T cell and germinal center differentiation. J Immunol 192(8):3607–3617. https://doi.org/10.4049/jimmunol.1301284CrossRefPubMed

101.

Wang L, Sun Y, Zhang Z, Jia Y, Zou Z, Ding J et al (2015) CXCR5+ CD4+ T follicular helper cells participate in the pathogenesis of primary biliary cirrhosis. Hepatology 61(2):627–638. https://doi.org/10.1002/hep.27306CrossRefPubMed

102.

Renand A, Cervera-Marzal I, Gil L, Dong C, Garcia A, Kervagoret E et al (2020) Integrative molecular profiling of autoreactive CD4 T cells in autoimmune hepatitis. J Hepatol 73(6):1379–1390. https://doi.org/10.1016/j.jhep.2020.05.053CrossRefPubMed

103.

Lino AC, Dorner T, Bar-Or A, Fillatreau S (2016) Cytokine-producing B cells: a translational view on their roles in human and mouse autoimmune diseases. Immunol Rev 269(1):130–144. https://doi.org/10.1111/imr.12374CrossRefPubMed

104.

Shen P, Fillatreau S (2015) Antibody-independent functions of B cells: a focus on cytokines. Nat Rev Immunol 15(7):441–451. https://doi.org/10.1038/nri3857CrossRefPubMed

105.

Wang AA, Gommerman JL, Rojas OL (2021) Plasma cells: from cytokine production to regulation in experimental autoimmune encephalomyelitis. J Mol Biol 433(1):166655. https://doi.org/10.1016/j.jmb.2020.09.014CrossRefPubMed

106.

Nishikawa H, Enomoto H, Iwata Y, Kishino K, Shimono Y, Hasegawa K et al (2016) B-cell activating factor belonging to the tumor necrosis factor family and interferon-gamma-inducible protein-10 in autoimmune hepaTitis. Medicine (Baltimore) 95(12):e3194. https://doi.org/10.1097/MD.0000000000003194CrossRef

107.

Czaja AJ (2022) Advancing biologic therapy for refractory autoimmune hepatitis. Dig Dis Sci 2022. https://doi.org/10.1007/s10620-021-07378-4

108.

Nishioji K, Okanoue T, Itoh Y, Narumi S, Sakamoto M, Nakamura H et al (2001) Increase of chemokine interferon-inducible protein-10 (IP-10) in the serum of patients with autoimmune liver diseases and increase of its mRNA expression in hepatocytes. Clin Exp Immunol 123(2):271–279. https://doi.org/10.1046/j.1365-2249.2001.01391.xCrossRefPubMedPubMedCentral

109.

Herkel J (2015) Regulatory T cells in hepatic immune tolerance and autoimmune liver diseases. Dig Dis 33(Suppl 2):70–74. https://doi.org/10.1159/000440750CrossRefPubMed

110.

Ye C, Brand D, Zheng SG (2018) Targeting IL-2: an unexpected effect in treating immunological diseases. Signal Transduct Target Ther 3:2. https://doi.org/10.1038/s41392-017-0002-5CrossRefPubMedPubMedCentral

111.

Lapierre P, Beland K, Yang R, Alvarez F (2013) Adoptive transfer of ex vivo expanded regulatory T cells in an autoimmune hepatitis murine model restores peripheral tolerance. Hepatology 57(1):217–227. https://doi.org/10.1002/hep.26023CrossRefPubMed

112.

Czaja AJ (2021) Exploring the pathogenic role and therapeutic implications of interleukin 2 in autoimmune hepatitis. Dig Dis Sci 66(8):2493–2512. https://doi.org/10.1007/s10620-020-06562-2CrossRefPubMed

113.

Lim TY, Martinez-Llordella M, Kodela E, Gray E, Heneghan MA, Sanchez-Fueyo A (2018) Low-dose interleukin-2 for refractory autoimmune hepatitis. Hepatology 68(4):1649–1652. https://doi.org/10.1002/hep.30059CrossRefPubMed

114.

Jones BE, Maerz MD, Buckner JH (2018) IL-6: a cytokine at the crossroads of autoimmunity. Curr Opin Immunol 55:9–14. https://doi.org/10.1016/j.coi.2018.09.002CrossRefPubMedPubMedCentral

115.

Barr TA, Shen P, Brown S, Lampropoulou V, Roch T, Lawrie S et al (2012) B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells. J Exp Med 209(5):1001–1010. https://doi.org/10.1084/jem.20111675CrossRefPubMedPubMedCentral

116.

Zhao L, Tang Y, You Z, Wang Q, Liang S, Han X et al (2011) Interleukin-17 contributes to the pathogenesis of autoimmune hepatitis through inducing hepatic interleukin-6 expression. PLoS ONE 6(4):e18909. https://doi.org/10.1371/journal.pone.0018909CrossRefPubMedPubMedCentral

117.

Yousefi A, Najafi M, Motamed F, Mahmoudi E, Bidoki AZ, Sadr M et al (2018) Association of interleukin-6 and interleukin-1 family gene polymorphisms in autoimmune hepatitis. Ann Hepatol 17(6):1021–1025. https://doi.org/10.5604/01.3001.0012.7202CrossRefPubMed

118.

von Borstel A, Abdulahad WH, Dekkema G, Rutgers A, Stegeman CA, Veldman J et al (2020) Mycophenolic acid and 6-mercaptopurine both inhibit B-cell proliferation in granulomatosis with polyangiitis patients, whereas only mycophenolic acid inhibits B-cell IL-6 production. PLoS ONE 15(7):e0235743. https://doi.org/10.1371/journal.pone.0235743CrossRef

119.

Shen P, Roch T, Lampropoulou V, O’Connor RA, Stervbo U, Hilgenberg E et al (2014) IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases. Nature 507(7492):366–370. https://doi.org/10.1038/nature12979CrossRefPubMedPubMedCentral

120.

Dang VD, Hilgenberg E, Ries S, Shen P, Fillatreau S (2014) From the regulatory functions of B cells to the identification of cytokine-producing plasma cell subsets. Curr Opin Immunol 28:77–83. https://doi.org/10.1016/j.coi.2014.02.009CrossRefPubMed

121.

Anderton SM, Fillatreau S (2008) Activated B cells in autoimmune diseases: the case for a regulatory role. Nat Clin Pract Rheumatol 4(12):657–666. https://doi.org/10.1038/ncprheum0950CrossRefPubMed

122.

Lohse AW, Kogel M, Meyer zumBuschenfelde KH (1995) Evidence for spontaneous immunosuppression in autoimmune hepatitis. Hepatology 22(2):381–8PubMed

123.

Tedder TF (2015) B10 cells: a functionally defined regulatory B cell subset. J Immunol 194(4):1395–1401. https://doi.org/10.4049/jimmunol.1401329CrossRefPubMed

124.

Thibodeau J, Bourgeois-Daigneault MC, Huppe G, Tremblay J, Aumont A, Houde M et al (2008) Interleukin-10-induced MARCH1 mediates intracellular sequestration of MHC class II in monocytes. Eur J Immunol 38(5):1225–1230. https://doi.org/10.1002/eji.200737902CrossRefPubMedPubMedCentral

125.

Matsuki Y, Ohmura-Hoshino M, Goto E, Aoki M, Mito-Yoshida M, Uematsu M et al (2007) Novel regulation of MHC class II function in B cells. EMBO J 26(3):846–854. https://doi.org/10.1038/sj.emboj.7601556CrossRefPubMedPubMedCentral

126.

Galbas T, Steimle V, Lapointe R, Ishido S, Thibodeau J (2012) MARCH1 down-regulation in IL-10-activated B cells increases MHC class II expression. Cytokine 59(1):27–30. https://doi.org/10.1016/j.cyto.2012.03.015CrossRefPubMed

127.

Choi J, Leung PS, Bowlus C, Gershwin ME (2015) IL-35 and Autoimmunity: a comprehensive perspective. Clin Rev Allergy Immunol 49(3):327–332. https://doi.org/10.1007/s12016-015-8468-9CrossRefPubMed

128.

Hu S, Lian PP, Hu Y, Zhu XY, Jiang SW, Ma Q et al (2020) The role of IL-35 in the pathophysiological processes of liver disease. Front Pharmacol 11:569575. https://doi.org/10.3389/fphar.2020.569575CrossRefPubMed

129.

Lian M, Zhang J, Zhao L, Chen X, Peng Y, Wang Q et al (2019) Interleukin-35 regulates immune microenvironment of autoimmune hepatitis through inducing the expansion of myeloid-derived suppressor cells. Front Immunol 10:2577. https://doi.org/10.3389/fimmu.2019.02577CrossRefPubMedPubMedCentral

130.

Vignali DA, Kuchroo VK (2012) IL-12 family cytokines: immunological playmakers. Nat Immunol 13(8):722–728. https://doi.org/10.1038/ni.2366CrossRefPubMedPubMedCentral

131.

Sartori A, Ma X, Gri G, Showe L, Benjamin D, Trinchieri G (1997) Interleukin-12: an immunoregulatory cytokine produced by B cells and antigen-presenting cells. Methods 11(1):116–127. https://doi.org/10.1006/meth.1996.0395CrossRefPubMed

132.

Sugimoto K, Ogawa A, Shimomura Y, Nagahama K, Mizoguchi A, Bhan AK (2007) Inducible IL-12-producing B cells regulate Th2-mediated intestinal inflammation. Gastroenterology 133(1):124–136. https://doi.org/10.1053/j.gastro.2007.03.112CrossRefPubMed

133.

Gil-Farina I, Di Scala M, Salido E, Lopez-Franco E, Rodriguez-Garcia E, Blasi M et al (2016) Transient expression of transgenic IL-12 in mouse liver triggers unremitting inflammation mimicking human autoimmune hepatitis. J Immunol 197(6):2145–2156. https://doi.org/10.4049/jimmunol.1600228CrossRefPubMed

134.

Manns MP, Czaja AJ, Gorham JD, Krawitt EL, Mieli-Vergani G, Vergani D et al (2010) Diagnosis and management of autoimmune hepatitis. Hepatology 51(6):2193–2213. https://doi.org/10.1002/hep.23584CrossRefPubMed

135.

Lohse AW, Sebode M, Jorgensen MH, Ytting H, Karlsen TH, Kelly D et al (2020) Second-line and third-line therapy for autoimmune hepatitis: a position statement from the European Reference Network on Hepatological Diseases and the International Autoimmune Hepatitis Group. J Hepatol 73(6):1496–1506. https://doi.org/10.1016/j.jhep.2020.07.023CrossRefPubMed

136.

Hardy RS, Raza K, Cooper MS (2020) Therapeutic glucocorticoids: mechanisms of actions in rheumatic diseases. Nat Rev Rheumatol 16(3):133–144. https://doi.org/10.1038/s41584-020-0371-yCrossRefPubMed

137.

Timmermans S, Souffriau J, Libert C (2019) A General introduction to glucocorticoid biology. Front Immunol 10:1545. https://doi.org/10.3389/fimmu.2019.01545CrossRefPubMedPubMedCentral

138.

Quatrini L, Ugolini S (2021) New insights into the cell- and tissue-specificity of glucocorticoid actions. Cell Mol Immunol 18(2):269–278. https://doi.org/10.1038/s41423-020-00526-2CrossRefPubMed

139.

Cain DW, Cidlowski JA (2017) Immune regulation by glucocorticoids. Nat Rev Immunol 17(4):233–247. https://doi.org/10.1038/nri.2017.1CrossRefPubMed

140.

Franco LM, Gadkari M, Howe KN, Sun J, Kardava L, Kumar P et al (2019) Immune regulation by glucocorticoids can be linked to cell type-dependent transcriptional responses. J Exp Med 216(2):384–406. https://doi.org/10.1084/jem.20180595CrossRefPubMedPubMedCentral

141.

Haneda M, Owaki M, Kuzuya T, Iwasaki K, Miwa Y, Kobayashi T (2014) Comparative analysis of drug action on B-cell proliferation and differentiation for mycophenolic acid, everolimus, and prednisolone. Transplantation 97(4):405–412. https://doi.org/10.1097/01.TP.0000441826.70687.f6CrossRefPubMed

142.

Yan SX, Deng XM, Wang QT, Sun XJ, Wei W (2015) Prednisone treatment inhibits the differentiation of B lymphocytes into plasma cells in MRL/MpSlac-lpr mice. Acta Pharmacol Sin 36(11):1367–1376. https://doi.org/10.1038/aps.2015.76CrossRefPubMedPubMedCentral

143.

Taubert R, Hardtke-Wolenski M, Noyan F, Wilms A, Baumann AK, Schlue J et al (2014) Intrahepatic regulatory T cells in autoimmune hepatitis are associated with treatment response and depleted with current therapies. J Hepatol 61(5):1106–1114. https://doi.org/10.1016/j.jhep.2014.05.034CrossRefPubMed

144.

Voetberg BJ, Garvy BA, Mayer HK, King LE, Fraker PJ (1994) Apoptosis accompanies a change in the phenotypic distribution and functional capacity of murine bone marrow B-cells chronically exposed to prednisolone. Clin Immunol Immunopathol 71(2):190–198. https://doi.org/10.1006/clin.1994.1071CrossRefPubMed

145.

Gruver-Yates AL, Quinn MA, Cidlowski JA (2014) Analysis of glucocorticoid receptors and their apoptotic response to dexamethasone in male murine B cells during development. Endocrinology 155(2):463–474. https://doi.org/10.1210/en.2013-1473CrossRefPubMed

146.

Shapiro-Shelef M, Lin KI, Savitsky D, Liao J, Calame K (2005) Blimp-1 is required for maintenance of long-lived plasma cells in the bone marrow. J Exp Med 202(11):1471–1476. https://doi.org/10.1084/jem.20051611CrossRefPubMedPubMedCentral

147.

Hiepe F, Dorner T, Hauser AE, Hoyer BF, Mei H, Radbruch A (2011) Long-lived autoreactive plasma cells drive persistent autoimmune inflammation. Nat Rev Rheumatol 7(3):170–178. https://doi.org/10.1038/nrrheum.2011.1CrossRefPubMed

148.

Broen JCA, van Laar JM (2020) Mycophenolate mofetil, azathioprine and tacrolimus: mechanisms in rheumatology. Nat Rev Rheumatol 16(3):167–78. https://doi.org/10.1038/s41584-020-0374-8CrossRefPubMed

149.

Tiede I, Fritz G, Strand S, Poppe D, Dvorsky R, Strand D et al (2003) CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 111(8):1133–1145. https://doi.org/10.1172/JCI16432CrossRefPubMedPubMedCentral

150.

Dimitriu A, Fauci AS (1978) Activation of human B lymphocytes XI Differential effects of azathioprine on B lymphocytes and lymphocyte subpopulations regulating B cell function. J Immunol 121(6):2335–9PubMed

151.

Walmsley MJ, Ooi SK, Reynolds LF, Smith SH, Ruf S, Mathiot A et al (2003) Critical roles for Rac1 and Rac2 GTPases in B cell development and signaling. Science 302(5644):459–462. https://doi.org/10.1126/science.1089709CrossRefPubMed

152.

Tareyeva IE, Shilov EM, Gordovskaya NB (1980) The effects of azathioprine and prednisolone on T- and B-lymphocytes in patients with lupus nephritis and chronic glomerulonephritis. Clin Nephrol 14(5):233–237PubMed

153.

Krieckaert CL, Bartelds GM, Lems WF, Wolbink GJ (2010) The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review. Arthritis Res Ther 12(5):217. https://doi.org/10.1186/ar3147CrossRefPubMedPubMedCentral

154.

Garces S, Demengeot J, Benito-Garcia E (2013) The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis 72(12):1947–1955. https://doi.org/10.1136/annrheumdis-2012-202220CrossRefPubMed

155.

Allison AC (2005) Mechanisms of action of mycophenolate mofetil. Lupus 14(Suppl 1):s2-8. https://doi.org/10.1191/0961203305lu2109oaCrossRefPubMed

156.

Carr SF, Papp E, Wu JC, Natsumeda Y (1993) Characterization of human type I and type II IMP dehydrogenases. J Biol Chem 268(36):27286–27290CrossRef

157.

Eickenberg S, Mickholz E, Jung E, Nofer JR, Pavenstadt HJ, Jacobi AM (2012) Mycophenolic acid counteracts B cell proliferation and plasmablast formation in patients with systemic lupus erythematosus. Arthritis Res Ther 14(3):R110. https://doi.org/10.1186/ar3835CrossRefPubMedPubMedCentral

158.

Bijl M, Horst G, Bootsma H, Limburg PC, Kallenberg CG (2003) Mycophenolate mofetil prevents a clinical relapse in patients with systemic lupus erythematosus at risk. Ann Rheum Dis 62(6):534–539. https://doi.org/10.1136/ard.62.6.534CrossRefPubMedPubMedCentral

159.

Karnell JL, Karnell FG 3rd, Stephens GL, Rajan B, Morehouse C, Li Y et al (2011) Mycophenolic acid differentially impacts B cell function depending on the stage of differentiation. J Immunol 187(7):3603–3612. https://doi.org/10.4049/jimmunol.1003319CrossRefPubMed

160.

Heidt S, Roelen DL, Eijsink C, van Kooten C, Claas FH, Mulder A (2008) Effects of immunosuppressive drugs on purified human B cells: evidence supporting the use of MMF and rapamycin. Transplantation 86(9):1292–1300. https://doi.org/10.1097/TP.0b013e3181874a36CrossRefPubMed

161.

Lee DSW, Rojas OL, Gommerman JL (2021) B cell depletion therapies in autoimmune disease: advances and mechanistic insights. Nat Rev Drug Discov 20(3):179–199. https://doi.org/10.1038/s41573-020-00092-2CrossRefPubMed

162.

Hofmann K, Clauder AK, Manz RA (2018) Targeting B cells and plasma cells in autoimmune diseases. Front Immunol 9:835. https://doi.org/10.3389/fimmu.2018.00835CrossRefPubMedPubMedCentral

163.

Frampton JE (2020) Rituximab: a review in pemphigus vulgaris. Am J Clin Dermatol 21(1):149–156. https://doi.org/10.1007/s40257-019-00497-9CrossRefPubMed

164.

Chen DM, Odueyungbo A, Csinady E, Gearhart L, Lehane P, Cheu M et al (2020) Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid-sparing effect. Br J Dermatol 182(5):1111–1119. https://doi.org/10.1111/bjd.18482CrossRefPubMed

165.

Favas C, Isenberg DA (2009) B-cell-depletion therapy in SLE–what are the current prospects for its acceptance? Nat Rev Rheumatol 5(12):711–716. https://doi.org/10.1038/nrrheum.2009.218CrossRefPubMed

166.

Burak KW, Swain MG, Santodomingo-Garzon T, Lee SS, Urbanski SJ, Aspinall AI et al (2013) Rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy. Can J Gastroenterol 27(5):273–280. https://doi.org/10.1155/2013/512624CrossRefPubMedPubMedCentral

167.

Than NN, Hodson J, Schmidt-Martin D, Taubert R, Wawman RE, Botter M et al (2019) Efficacy of rituximab in difficult-to-manage autoimmune hepatitis: results from the international autoimmune hepatitis group. JHEP Rep 1(6):437–445. https://doi.org/10.1016/j.jhepr.2019.10.005CrossRefPubMedPubMedCentral

168.

Buitrago-Molina LE, Dywicki J, Noyan F, Schepergerdes L, Pietrek J, Lieber M et al (2021) Anti-CD20 therapy alters the protein signature in experimental murine AIH, but not exclusively towards regeneration. Cells 10(6). https://doi.org/10.3390/cells10061471

169.

Mackay F, Schneider P, Rennert P, Browning J (2003) BAFF AND APRIL: a tutorial on B cell survival. Annu Rev Immunol 21:231–264. https://doi.org/10.1146/annurev.immunol.21.120601.141152CrossRefPubMed

170.

Bossen C, Schneider P (2006) BAFF, APRIL and their receptors: structure, function and signaling. Semin Immunol 18(5):263–275. https://doi.org/10.1016/j.smim.2006.04.006CrossRefPubMed

171.

Mackay F, Schneider P (2009) Cracking the BAFF code. Nat Rev Immunol 9(7):491–502. https://doi.org/10.1038/nri2572CrossRefPubMed

172.

Vincent FB, Morand EF, Schneider P, Mackay F (2014) The BAFF/APRIL system in SLE pathogenesis. Nat Rev Rheumatol 10(6):365–373CrossRef

173.

Nakayamada S, Tanaka Y (2016) BAFF- and APRIL-targeted therapy in systemic autoimmune diseases. Inflamm Regen 36:6. https://doi.org/10.1186/s41232-016-0015-4CrossRefPubMedPubMedCentral

174.

Stadanlick JE, Cancro MP (2008) BAFF and the plasticity of peripheral B cell tolerance. Curr Opin Immunol 20(2):158–161. https://doi.org/10.1016/j.coi.2008.03.015CrossRefPubMedPubMedCentral

175.

Migita K, Abiru S, Maeda Y, Nakamura M, Komori A, Ito M et al (2007) Elevated serum BAFF levels in patients with autoimmune hepatitis. Hum Immunol 68(7):586–591. https://doi.org/10.1016/j.humimm.2007.03.010CrossRefPubMed

176.

McWilliams EM, Lucas CR, Chen T, Harrington BK, Wasmuth R, Campbell A et al (2019) Anti-BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib. Blood Adv 3(3):447–460. https://doi.org/10.1182/bloodadvances.2018025684CrossRefPubMedPubMedCentral

177.

Dorner T, Posch MG, Li Y, Petricoul O, Cabanski M, Milojevic JM et al (2019) Treatment of primary Sjogren’s syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity. Ann Rheum Dis 78(5):641–647. https://doi.org/10.1136/annrheumdis-2018-214720CrossRefPubMed

178.

Wise LM, Stohl W (2020) Belimumab and rituximab in systemic lupus erythematosus: a tale of two B cell-targeting agents. Front Med (Lausanne) 7:303. https://doi.org/10.3389/fmed.2020.00303CrossRef

179.

Blair HA, Duggan ST (2018) Belimumab: a review in systemic lupus erythematosus. Drugs 78(3):355–366. https://doi.org/10.1007/s40265-018-0872-zCrossRefPubMed

180.

Arvaniti P, Giannoulis G, Gabeta S, Zachou K, Koukoulis GK, Dalekos GN (2020) Belimumab is a promising third-line treatment option for refractory autoimmune hepatitis. JHEP Rep 2(4):100123. https://doi.org/10.1016/j.jhepr.2020.100123CrossRefPubMedPubMedCentral

181.

Blair HA, Deeks ED (2017) Abatacept: a review in rheumatoid arthritis. Drugs 77(11):1221–1233. https://doi.org/10.1007/s40265-017-0775-4CrossRefPubMed

182.

Lorenzetti R, Janowska I, Smulski CR, Frede N, Henneberger N, Walter L et al (2019) Abatacept modulates CD80 and CD86 expression and memory formation in human B-cells. J Autoimmun 101:145–152. https://doi.org/10.1016/j.jaut.2019.04.016CrossRefPubMed

183.

Grasland A, Sterpu R, Boussoukaya S, Mahe I (2012) Autoimmune hepatitis induced by adalimumab with successful switch to abatacept. Eur J Clin Pharmacol 68(5):895–898. https://doi.org/10.1007/s00228-011-1191-4CrossRefPubMed

184.

Elfeki MA, Genco PV, Pungpapong S, Nakhleh RE, Nguyen JH, Harnois DM (2014) Abatacept use in graft-versus-host disease after orthotopic liver transplantation: a case report. Transplant Proc 46(7):2422–2425. https://doi.org/10.1016/j.transproceed.2014.06.061CrossRefPubMed

185.

Watkins B, Qayed M, McCracken C, Bratrude B, Betz K, Suessmuth Y et al (2021) Phase II trial of costimulation blockade with abatacept for prevention of acute GVHD. J Clin Oncol 39(17):1865–1877. https://doi.org/10.1200/JCO.20.01086

186.

Bowman SJ, Fox R, Dorner T, Mariette X, Papas A, Grader-Beck T et al (2022) Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjogren’s syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial. Lancet 399(10320):161–171. https://doi.org/10.1016/S0140-6736(21)02251-0CrossRefPubMed

187.

Bontscho J, Schreiber A, Manz RA, Schneider W, Luft FC, Kettritz R (2011) Myeloperoxidase-specific plasma cell depletion by bortezomib protects from anti-neutrophil cytoplasmic autoantibodies-induced glomerulonephritis. J Am Soc Nephrol 22(2):336–348. https://doi.org/10.1681/ASN.2010010034CrossRefPubMedPubMedCentral

188.

Gomez AM, Vrolix K, Martinez-Martinez P, Molenaar PC, Phernambucq M, van der Esch E et al (2011) Proteasome inhibition with bortezomib depletes plasma cells and autoantibodies in experimental autoimmune myasthenia gravis. J Immunol 186(4):2503–2513. https://doi.org/10.4049/jimmunol.1002539CrossRefPubMed

189.

Taddeo A, Khodadadi L, Voigt C, Mumtaz IM, Cheng Q, Moser K et al (2015) Long-lived plasma cells are early and constantly generated in New Zealand Black/New Zealand white F1 mice and their therapeutic depletion requires a combined targeting of autoreactive plasma cells and their precursors. Arthritis Res Ther 17:39. https://doi.org/10.1186/s13075-015-0551-3CrossRefPubMedPubMedCentral

190.

Rosenberg AS, Pariser AR, Diamond B, Yao L, Turka LA, Lacana E et al (2016) A role for plasma cell targeting agents in immune tolerance induction in autoimmune disease and antibody responses to therapeutic proteins. Clin Immunol 165:55–59. https://doi.org/10.1016/j.clim.2016.02.009CrossRefPubMed

191.

Mehta B, Mahadeo K, Zaw R, Tang S, Kapoor N, Abdel-Azim H (2014) Bortezomib for effective treatment of a child with refractory autoimmune hemolytic anemia post allogeneic hematopoietic stem cell transplant. Pediatr Blood Cancer 61(12):2324–2325. https://doi.org/10.1002/pbc.25172CrossRefPubMed

192.

Jakez-Ocampo J, Atisha-Fregoso Y, Llorente L (2015) Refractory primary Sjogren syndrome successfully treated with bortezomib. J Clin Rheumatol 21(1):31–32. https://doi.org/10.1097/RHU.0000000000000210CrossRefPubMed

193.

Verbrugge SE, Scheper RJ, Lems WF, de Gruijl TD, Jansen G (2015) Proteasome inhibitors as experimental therapeutics of autoimmune diseases. Arthritis Res Ther 17:17. https://doi.org/10.1186/s13075-015-0529-1CrossRefPubMedPubMedCentral

194.

Khandelwal P, Davies SM, Grimley MS, Jordan MB, Curtis BR, Jodele S et al (2014) Bortezomib for refractory autoimmunity in pediatrics. Biol Blood Marrow Transplant 20(10):1654–1659. https://doi.org/10.1016/j.bbmt.2014.06.032CrossRefPubMed

195.

Yates S, Matevosyan K, Rutherford C, Shen YM, Sarode R (2014) Bortezomib for chronic relapsing thrombotic thrombocytopenic purpura: a case report. Transfusion 54(8):2064–2067. https://doi.org/10.1111/trf.12614CrossRefPubMed

196.

van Balen T, Schreuder MF, de Jong H, van de Kar NC (2014) Refractory thrombotic thrombocytopenic purpura in a 16-year-old girl: successful treatment with bortezomib. Eur J Haematol 92(1):80–82. https://doi.org/10.1111/ejh.12206CrossRefPubMed

197.

Gomez AM, Willcox N, Molenaar PC, Buurman W, Martinez-Martinez P, De Baets MH et al (2012) Targeting plasma cells with proteasome inhibitors: possible roles in treating myasthenia gravis? Ann N Y Acad Sci 1274:48–59. https://doi.org/10.1111/j.1749-6632.2012.06824.xCrossRefPubMed

198.

Danchaivijitr P, Yared J, Rapoport AP (2011) Successful treatment of IgG and complement-mediated autoimmune hemolytic anemia with bortezomib and low-dose cyclophosphamide. Am J Hematol 86(3):331–332. https://doi.org/10.1002/ajh.21950CrossRefPubMed

199.

Hiepe F, Radbruch A (2016) Plasma cells as an innovative target in autoimmune disease with renal manifestations. Nat Rev Nephrol 12(4):232–240. https://doi.org/10.1038/nrneph.2016.20CrossRefPubMed

200.

Mauri C, Menon M (2015) The expanding family of regulatory B cells. Int Immunol 27(10):479–486. https://doi.org/10.1093/intimm/dxv038CrossRefPubMedPubMedCentral

201.

Barr TA, Brown S, Mastroeni P, Gray D (2010) TLR and B cell receptor signals to B cells differentially program primary and memory Th1 responses to Salmonella enterica. J Immunol 185(5):2783–2789. https://doi.org/10.4049/jimmunol.1001431CrossRefPubMed

202.

Muscate F, Woestemeier A, Gagliani N (2021) Functional heterogeneity of CD4(+) T cells in liver inflammation. Semin Immunopathol 43(4):549–561. https://doi.org/10.1007/s00281-021-00881-wCrossRefPubMedPubMedCentral

203.

Parodis I, Stockfelt M, Sjowall C (2020) B Cell therapy in systemic lupus erythematosus: from rationale to clinical practice. Front Med (Lausanne) 7:316. https://doi.org/10.3389/fmed.2020.00316CrossRef

204.

Wu F, Gao J, Kang J, Wang X, Niu Q, Liu J et al (2021) B cells in rheumatoid arthritispathogenic mechanisms and treatment prospects. Front Immunol 12:750753. https://doi.org/10.3389/fimmu.2021.750753CrossRefPubMedPubMedCentral

205.

Terziroli Beretta-Piccoli B, Mieli-Vergani G, Vergani D (2021) Autoimmune hepatitis: serum autoantibodies in clinical practice. Clin Rev Allergy Immunol. https://doi.org/10.1007/s12016-021-08888-9

206.

Villalta D, Girolami E, Alessio MG, Sorrentino MC, Tampoia M, Brusca I et al (2016) Autoantibody profiling in a cohort of pediatric and adult patients with autoimmune hepatitis. J Clin Lab Anal 30(1):41–46. https://doi.org/10.1002/jcla.21813CrossRefPubMed

207.

Strassburg CP, Obermayer-Straub P, Alex B, Durazzo M, Rizzetto M, Tukey RH et al (1996) Autoantibodies against glucuronosyltransferases differ between viral hepatitis and autoimmune hepatitis. Gastroenterology 111(6):1576–1586. https://doi.org/10.1016/s0016-5085(96)70020-3CrossRefPubMed

208.

Martini E, Abuaf N, Cavalli F, Durand V, Johanet C, Homberg JC (1988) Antibody to liver cytosol (anti-LC1) in patients with autoimmune chronic active hepatitis type 2. Hepatology 8(6):1662–1666. https://doi.org/10.1002/hep.1840080632CrossRefPubMed

209.

Kanzler S, Weidemann C, Gerken G, Lohr HF, Galle PR, Meyer zumBuschenfelde KH et al (1999) Clinical significance of autoantibodies to soluble liver antigen in autoimmune hepatitis. J Hepatol 31(4):635–40CrossRef

210.

Ballot E, Homberg JC, Johanet C (2000) Antibodies to soluble liver antigen: an additional marker in type 1 auto-immune hepatitis. J Hepatol 33(2):208–215. https://doi.org/10.1016/s0168-8278(00)80361-xCrossRefPubMed

211.

Czaja AJ, Donaldson PT, Lohse AW (2002) Antibodies to soluble liver antigen/liver pancreas and HLA risk factors for type 1 autoimmune hepatitis. Am J Gastroenterol 97(2):413–419. https://doi.org/10.1111/j.1572-0241.2002.05479.xCrossRefPubMed

212.

Kirstein MM, Metzler F, Geiger E, Heinrich E, Hallensleben M, Manns MP et al (2015) Prediction of short- and long-term outcome in patients with autoimmune hepatitis. Hepatology 62(5):1524–1535. https://doi.org/10.1002/hep.27983CrossRefPubMed

213.

Rigopoulou EI, Roggenbuck D, Smyk DS, Liaskos C, Mytilinaiou MG, Feist E et al (2012) Asialoglycoprotein receptor (ASGPR) as target autoantigen in liver autoimmunity: lost and found. Autoimmun Rev 12(2):260–269. https://doi.org/10.1016/j.autrev.2012.04.005CrossRefPubMed

214.

Manns MP, Strassburg CP (2001) Autoimmune hepatitis: clinical challenges. Gastroenterology 120(6):1502–1517. https://doi.org/10.1053/gast.2001.24227CrossRefPubMed

215.

Zauli D, Ghetti S, Grassi A, Descovich C, Cassani F, Ballardini G et al (1997) Anti-neutrophil cytoplasmic antibodies in type 1 and 2 autoimmune hepatitis. Hepatology 25(5):1105–1107. https://doi.org/10.1002/hep.510250510CrossRefPubMed

216.

Terjung B, Bogsch F, Klein R, Sohne J, Reichel C, Wasmuth JC et al (2004) Diagnostic accuracy of atypical p-ANCA in autoimmune hepatitis using ROC- and multivariate regression analysis. Eur J Med Res 9(9):439–448PubMed

217.

Sonthalia N, Rathi PM, Jain SS, Surude RG, Mohite AR, Pawar SV et al (2017) Natural history and treatment outcomes of severe autoimmune hepatitis. J Clin Gastroenterol 51(6):548–556. https://doi.org/10.1097/MCG.0000000000000805CrossRefPubMed

218.

Bergantini L, d’Alessandro M, Cameli P, Vietri L, Vagaggini C, Perrone A et al (2020) Effects of rituximab therapy on B cell differentiation and depletion. Clin Rheumatol 39(5):1415–1421. https://doi.org/10.1007/s10067-020-04996-7CrossRefPubMed

219.

Myhr KM, Torkildsen O, Lossius A, Bo L, Holmoy T (2019) B cell depletion in the treatment of multiple sclerosis. Expert Opin Biol Ther 19(3):261–271. https://doi.org/10.1080/14712598.2019.1568407CrossRefPubMed

220.

Babiker HM, Glode AE, Cooke LS, Mahadevan D (2018) Ublituximab for the treatment of CD20 positive B-cell malignancies. Expert Opin Investig Drugs 27(4):407–412. https://doi.org/10.1080/13543784.2018.1459560CrossRefPubMed

221.

Freeman CL, Sehn LH (2018) A tale of two antibodies: obinutuzumab versus rituximab. Br J Haematol 182(1):29–45. https://doi.org/10.1111/bjh.15232CrossRefPubMed

222.

Cartron G, Watier H (2017) Obinutuzumab: what is there to learn from clinical trials? Blood 130(5):581–589. https://doi.org/10.1182/blood-2017-03-771832CrossRefPubMed

223.

Chen D, Gallagher S, Monson NL, Herbst R, Wang Y (2016) Inebilizumab, a B cell-depleting anti-CD19 antibody for the treatment of autoimmune neurological diseases: insights from preclinical studies. J Clin Med 5(12). https://doi.org/10.3390/jcm5120107

224.

Zhao Q (2020) Bispecific antibodies for autoimmune and inflammatory diseases: clinical progress to date. BioDrugs 34(2):111–119. https://doi.org/10.1007/s40259-019-00400-2CrossRefPubMed

225.

Chu SY, Pong E, Bonzon C, Yu N, Jacob CO, Chalmers SA et al (2021) Inhibition of B cell activation following in vivo co-engagement of B cell antigen receptor and Fcgamma receptor IIb in non-autoimmune-prone and SLE-prone mice. J Transl Autoimmun 4:100075. https://doi.org/10.1016/j.jtauto.2020.100075CrossRefPubMed

226.

Stohl W, Hiepe F, Latinis KM, Thomas M, Scheinberg MA, Clarke A et al (2012) Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum 64(7):2328–2337. https://doi.org/10.1002/art.34400CrossRefPubMedPubMedCentral

227.

Ramskold D, Parodis I, Lakshmikanth T, Sippl N, Khademi M, Chen Y et al (2019) B cell alterations during BAFF inhibition with belimumab in SLE. EBioMedicine 40:517–527. https://doi.org/10.1016/j.ebiom.2018.12.035CrossRefPubMed

228.

Bonelli M, Scheinecker C (2018) How does abatacept really work in rheumatoid arthritis? Curr Opin Rheumatol 30(3):295–300. https://doi.org/10.1097/BOR.0000000000000491CrossRefPubMed

Keynote webinar | Spotlight on medication adherence

Springer Medicine

B cells in autoimmune hepatitis: bystanders or central players?

Abstract

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2022

Challenges and opportunities in achieving effective regulatory T cell therapy in autoimmune liver disease

Harnessing the liver to induce antigen-specific immune tolerance

Cellular senescence in the cholangiopathies: a driver of immunopathology and a novel therapeutic target

The intestinal and biliary microbiome in autoimmune liver disease—current evidence and concepts

Tolerance and autoimmunity in the liver

Bile acids and their receptors: modulators and therapeutic targets in liver inflammation

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials